A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus
Abstract The optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is still a debatable point; however, randomized trials for strategies including neoadjuvant or adjuvant chemotherapy (CT), radiotherapy, or chemoradiotherapy (CRT) are not always available. This network meta-anal...
Guardado en:
Autores principales: | Yunpeng Zhao, Yongqiang Wang, Lei Shan, Chuanliang Peng, Wenhao Zhang, Xiaogang Zhao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/84c636098a304efe881a0c8968f6f874 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
por: Mitsuro Kanda, et al.
Publicado: (2021) -
Learning curve for minimally invasive oesophagectomy of oesophageal cancer and survival analysis
por: Yunpeng Zhao, et al.
Publicado: (2021) -
Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
por: Guocan Yu, et al.
Publicado: (2021) -
Synchronous Hodgkin’s Lymphoma and Adenocarcinoma of the Lung with Metachronous Squamous Cell Carcinoma of Esophagus – A Rare Case Report
por: Aswin Nagarajan, et al.
Publicado: (2021) -
Oral rehabilitation after squamous cell carcinoma mandibular resection
por: Dimmock Mylène, et al.
Publicado: (2021)